Lupin settles patent dispute with Astellas Pharma to keep selling bladder drug in US

Lupin will pay ninety million dollars to Astellas Pharma to settle a patent dispute over its generic bladder drug. This deal allows sales to continue in the US.

洞察:
Lupin Limited , headquartered in India ININ, has officially settled a patent infringement dispute with Japan JPJP based Astellas Pharma Inc. regarding the bladder drug Mirabegron (Myrbetriq). The settlement, finalized on February 10, 2026, resolves all pending litigation between the parties and allows Lupin to continue marketing the medication in the United States USUS.
The logo of Lupin, India's second-largest drugmaker, is seen on the facade of its pharmaceutical plant in Verna, Goa, India, on June 9, 2017. REUTERS/Danish Siddiqui/File Photo
The logo of Lupin, India's second-largest drugmaker, is seen on the facade of its pharmaceutical plant in Verna, Goa, India, on June 9, 2017. REUTERS/Danish Siddiqui/File Photo